CYTOMX THERAPEUTICS INC

NASDAQ: CTMX (CytomX Therapeutics, Inc.)

Kemas kini terakhir: 28 minit lalu

2.02

-0.02 (-1.23%)

Penutupan Terdahulu 2.04
Jumlah Dagangan 693,367
Harga / Jualan (P/S) 28.42
Harga / Buku (P/B) 1.55
Julat 52 Minggu
1.90 (-5%) — 8.21 (307%)
Margin Keuntungan 28.19%
Margin Operasi (TTM) 44.43%
EPS Cair (TTM) 0.480
Pertumbuhan Hasil Suku Tahunan (YOY) 22.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 70.60%
Jumlah Hutang/Ekuiti (D/E MRQ) 32.53%
Nisbah Semasa (MRQ) 1.73
Aliran Tunai Operasi (OCF TTM) -81.23 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -53.07 M
Pulangan Atas Aset (ROA TTM) 15.87%

AISkor Stockmoo

-0.3
Nilai 30% 3.4
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Harga rendah berbanding pertumbuhan perolehannya. info
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Hutang rendah. Keuntungan kukuh. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan atas Modal info NA
Masa 30% -4.0
Daripada analisis teknikal AI kami terhadap carta. info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Corak Lilin info NA
Aliran bagi Tempoh Pegangan Anda info NA
Sentimen 20% 0.0
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini bercampur atau neutral. info
Wang Pintar 20% -0.7
Aktiviti Orang Dalam info NA
Institusi bersih -0.08% daripada saham dalam pemfailan 13F terkini: 114 pemegang menambah, 75 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +35.0% dari 31 Aug hingga 30 Oct 2026, 12 hari untuk tutup (FINRA). info
Keadaan pasaran dan sektor lemah.
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Tidak dikira dalam skor
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Harga di antara sokongan dan rintangan. Paras sokongan dan rintangan menaik. info
Skor Akhir -0.30

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok CytomX Therapeutics, Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CTMX - - - 1.55
OPT 583 M - - 4.31
OCUP 51 M - - 0.870
ZYME - - - 7.29
PBYI - - - 2.73
ORMP - 6.74% - 0.530

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 0.83%
% Dimiliki oleh Institusi 47.10%

Pemilikan

Nama Tarikh Syer Dipegang
Elmind Capital, Lp 30 Jun 2026 4,550,000

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 103.35%

Kedudukan Pemegang Saham
Bertambah 114 29,761,343
Berkurang 75 28,757,015
Baharu 46 5,112,628
Dijual habis 32 6,286,727

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 45,246,966 12.0
15 Oct 2026 42,790,446 13.8
30 Sep 2026 40,813,393 8.7
15 Sep 2026 38,639,220 9.3
31 Aug 2026 33,512,293 11.8
14 Aug 2026 34,619,999 15.9

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

1 Positif 1 Negatif 4 Neutral
Tarikh Jenis Butiran
06 Nov 2026 Yahoo Finance CytomX (CTMX) Q3 2026 Earnings Call Transcript
Lower diarrhea rates emerge, but toxicity control remains the key test.
05 Nov 2026 Yahoo Finance CytomX Therapeutics Q3 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027. The update is expected to include the first look at overall survival data…
05 Nov 2026 Yahoo Finance CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 0.00% and -59.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
05 Nov 2026 Yahoo Finance CytomX Therapeutics: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — CytomX Therapeutics Inc.
05 Nov 2026 Yahoo Finance CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase…
02 Nov 2026 Yahoo Finance CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November. Guggenheim 3rd Annual…
29 Oct 2026 Yahoo Finance CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S.…
01 Sep 2026 Yahoo Finance CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Wells Fargo 21st Annual…
27 Aug 2026 Yahoo Finance CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.…

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda